These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. In utero transplantation of haemopoietic stem cells. Flake AW Best Pract Res Clin Haematol; 2001 Dec; 14(4):671-83. PubMed ID: 11924915 [TBL] [Abstract][Full Text] [Related]
66. The biology and ethics of banking fetal liver hematopoietic stem cells for in utero transplantation. Mychaliska GB; Muench MO; Rice HE; Leavitt AD; Cruz J; Harrison MR J Pediatr Surg; 1998 Feb; 33(2):394-9. PubMed ID: 9498425 [TBL] [Abstract][Full Text] [Related]
73. Fetal Surgical conditions and the unraveling of maternal-fetal tolerance. MacKenzie TC J Pediatr Surg; 2016 Feb; 51(2):197-9. PubMed ID: 26653947 [TBL] [Abstract][Full Text] [Related]
74. Efficient engraftment of in utero transplanted mice with retrovirally transduced hematopoietic stem cells. Rio P; Martinez-Palacio J; Ramirez A; Bueren JA; Segovia JC Gene Ther; 2005 Feb; 12(4):358-63. PubMed ID: 15550924 [TBL] [Abstract][Full Text] [Related]
75. Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies. Ureña-Bailén G; Block M; Grandi T; Aivazidou F; Quednau J; Krenz D; Daniel-Moreno A; Lamsfus-Calle A; Epting T; Handgretinger R; Wild S; Mezger M CRISPR J; 2023 Feb; 6(1):5-16. PubMed ID: 36662546 [TBL] [Abstract][Full Text] [Related]
76. The hopes and fears of in utero gene therapy for genetic disease--a review. Coutelle C; Themis M; Waddington S; Gregory L; Nivsarkar M; Buckley S; Cook T; Rodeck C; Peebles D; David A Placenta; 2003 Oct; 24 Suppl B():S114-21. PubMed ID: 14559040 [TBL] [Abstract][Full Text] [Related]
77. Transplacental Gene Delivery (TPGD) as a Noninvasive Tool for Fetal Gene Manipulation in Mice. Nakamura S; Watanabe S; Ando N; Ishihara M; Sato M Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31775372 [TBL] [Abstract][Full Text] [Related]
78. Global Transcriptional Response to CRISPR/Cas9-AAV6-Based Genome Editing in CD34 Cromer MK; Vaidyanathan S; Ryan DE; Curry B; Lucas AB; Camarena J; Kaushik M; Hay SR; Martin RM; Steinfeld I; Bak RO; Dever DP; Hendel A; Bruhn L; Porteus MH Mol Ther; 2018 Oct; 26(10):2431-2442. PubMed ID: 30005866 [TBL] [Abstract][Full Text] [Related]
79. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice. Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487 [TBL] [Abstract][Full Text] [Related]
80. Answered and Unanswered Questions in Early-Stage Viral Vector Transduction Biology and Innate Primary Cell Toxicity for Dudek AM; Porteus MH Front Immunol; 2021; 12():660302. PubMed ID: 34122418 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]